KR101514011B1 - Food composition with cetylated fatty for alleviaton of symptoms and pains - Google Patents

Food composition with cetylated fatty for alleviaton of symptoms and pains Download PDF

Info

Publication number
KR101514011B1
KR101514011B1 KR1020140052533A KR20140052533A KR101514011B1 KR 101514011 B1 KR101514011 B1 KR 101514011B1 KR 1020140052533 A KR1020140052533 A KR 1020140052533A KR 20140052533 A KR20140052533 A KR 20140052533A KR 101514011 B1 KR101514011 B1 KR 101514011B1
Authority
KR
South Korea
Prior art keywords
weight
fatty acid
pain
food composition
arthritis
Prior art date
Application number
KR1020140052533A
Other languages
Korean (ko)
Inventor
이정
탁상범
Original Assignee
티케이엘 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 티케이엘 주식회사 filed Critical 티케이엘 주식회사
Priority to KR1020140052533A priority Critical patent/KR101514011B1/en
Application granted granted Critical
Publication of KR101514011B1 publication Critical patent/KR101514011B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A23B - A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A23B - A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L21/00Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
    • A23L21/20Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
    • A23L21/25Honey; Honey substitutes
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A23B - A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/238Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum

Abstract

The present invention relates to a food composition for alleviating symptoms and pain of arthritis on joint of knees including a cetylated fatty acid as an active ingredient, having an effect of alleviating symptoms and pain of arthritis on joint of knees where provided is a food composition for alleviating symptoms and pain of arthritis on joint of knees including a cetylated fatty acid produced by making cetyl alcohol react with fatty acid in an esterification reaction as an active ingredient.

Description

TECHNICAL FIELD The present invention relates to a composition for treating knee osteoarthritis and pain relief comprising cetylated fatty acid as an active ingredient,

The present invention relates to a knee joint symptom and a food composition for relieving pain, and more particularly, to a knee joint symptom and a food composition for relieving pain which contains a cetylated fatty acid as an active ingredient.

Arthritis is a chronic disease in which 5% of the population of Korea suffer from arthritis synovitis, which causes edema and pain. Arthritis is a progressive disease and causes joint deformity and disability and continues to worsen if left untreated, with serious consequences.

Degenerative knee osteoarthritis, also known as knee arthritis, is the most common arthritis in arthritic diseases. It occurs mainly in middle-aged or elderly people. As age increases, both men and women increase steadily.

The direct causes of arthritis have not yet been clearly elucidated. For the treatment, steroids such as cortisone and other corticosteroids, non-steroidal anti-inflammatory drugs such as aspirin, piroxicam and indomethacin, Anti-rheumatic agents such as D-penicillamine, antifungals such as colchicine, and immunosuppressants such as cyclophosphamide, azathioprine, methotrexate and rebamisole are commonly used. However, these chemotherapeutic agents do not exhibit fundamental therapeutic effects, and steroid hormones are limited in their use due to side effects. In addition, aspirin agents and botazoline agents, which are widely used as agents for alleviating joint pain and eliminating inflammation, have a fatal effect on humans, and it is impossible to continuously take the necessary amount to treat arthritis.

These conventional chemotherapeutic agents have disadvantages such as side effects that make long-term use of medicines difficult, and decrease of anti-inflammatory effects in long-term use. At present, indomethacin and furupenic acid, which are excellent in analgesic action, and various non-steroidal anti-inflammatory agents are used.

Therefore, development of a therapeutic agent for arthritis which is effective in solving such a problem and showing effects on inflammatory symptoms and pain is required, and it is very important to develop an agent having a low side effect since arthritis treating medication is required for a long time. In addition, some of the existing medicines are administered by intravenous or intraperitoneal injection. In this case, not only troublesome but also allergic, shock, and hygiene problems may occur.

Korean Patent No. 10-1338941 (Registration date: 2013.12.03) contains 50 to 150 mg of 20-Hydroxyecdysone per 100 g of the dry weight of the fermented milk-containing extract, Containing extract for the prevention and treatment of osteoarthritis or rheumatoid arthritis, which is characterized in that the fermenting bacteria of astaxanthin contained in the extract containing Bacillus subtilis is Bacillus subtilis. Korean Patent No. 10-1321754 (Registration Date: Oct. 31, 2013) discloses a composition comprising 350 to 450 parts by weight of sea tangle, 350 to 450 parts by weight of corn, and 50 to 150 parts by weight of purified water, And 50 to 150 parts by weight of a second extract obtained by mixing the extract of the present invention as an active ingredient, and a composition for improving or treating rheumatoid arthritis and osteoarthritis.

The present invention provides a symptom of knee osteoarthritis and a food composition for relieving pain, which comprises a cetylated fatty acid produced by esterifying a fatty acid and cetyl alcohol as an active ingredient.

In order to achieve the above object, the present invention provides a symptom of knee osteoarthritis and a food composition for relieving pain comprising cetylated fatty acid as an active ingredient.

The cetylated fatty acid used in the present invention is also called cetyl fatty acid, and can be prepared by esterifying a fatty acid and cetyl alcohol. In the present invention, the catechol fatty acid-containing food of the present invention was ingested in patients with knee osteoarthritis. As a result, it was confirmed that knee osteoarthritis was alleviated and the present invention was completed.

On the other hand, in the knee osteoarthritis symptom and the pain relieving food composition of the present invention, the fatty acid may preferably be C14 to C20. And more preferably myristoleic acid. Misteriolene can be obtained, for example, from beef tallow.

In the case of the knee joint symptom and the pain relieving food composition of the present invention, the cetylated fatty acid may be cetyl myristoleate prepared by adding cetyl alcohol to misteroolic acid and cetyl- Lt; / RTI > The generic IUPAC name for cetyl myristoleate is (Z) -hexadecyl ester tetradecenoic acid, the molecular formula is C 30 H 58 O 2 , the molecular weight is 450.7803 g / mol and the chemical formula is as follows.

Figure 112014041634311-pat00001

<Cetyl myristoleate chemical structure>

The present invention also relates to a food composition for alleviating knee osteoarthritis and pain, which comprises cetylated fatty acid as an active ingredient, wherein the cetylated fatty acid is preferably contained in an amount of 5 to 70% by weight based on the food composition. When the amount is less than 5% by weight, the effect is insufficient. When the amount is more than 70% by weight, the increase in the effect on the amount used is insufficient, which is uneconomical.

Meanwhile, the formulation of the food composition for knee osteoarthritis and pain relief according to the present invention may be, for example, meat, cereal, caffeinated beverages, ordinary beverages, chocolates, pastries, snacks, confectioneries, pizza, jelly, noodles, gums, Beverages, drinks, vitamin complexes, and other health supplement foods, but the present invention is not limited thereto.

The food composition containing the cetylated fatty acid of the present invention as an active ingredient has an effect on knee arthritis symptoms and pain relief.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the scope of the present invention is not limited to the following embodiments, and includes modifications of equivalent technical ideas.

[Example 1: preparation of cetylated fatty acid]

Water was added to the woji and then hydrolyzed at 170 ° C and 100 psi. Through the hydrolysis reaction, the fatty acid was separated into glycerol, and glycerin was removed through the process of falling below the countercurrent hydrolysis column.

After the hydrolysis was continued for 12 hours, the fatty acid from which the distilled glycerin had been removed was transferred to a trapper, and the hydrolysis was repeated once to remove glycerin as much as possible to purify the fatty acid.

The purified fatty acids were then concentrated at 60 &lt; 0 &gt; C, vacuum degree 150 mmAq for 5 hours.

The concentrated fatty acid was heated to 200 ° C to be in a fluid state, and cetyl alcohol was added thereto to esterify and cool water to remove the water to produce a waxy cetylated fatty acid. The wax-form cetylated fatty acid thus prepared contains 27 to 32% by weight of cetyl myristoleic acid.

[ Experimental Example  One: Cetylation  Fatty Arthritis of the knee  Symptom relieving effect confirmation - effectiveness evaluation]

To evaluate the symptom relief effect of the cilantylated fatty acid prepared in Example 1 in a patient with knee osteoarthritis, a double-blind, placebo-controlled, double-blind, placebo-controlled,

40 subjects were given 500 mg capsicum fatty acid [31.25% by weight of cetyl myristoleic acid 30% wax (the cetylated fatty acid of the present invention obtained in Example 1 above + 68.75% by weight of soybean oil)] twice daily In the morning and evening, 2 capsules total 4 capsules for a total of 12 weeks. The knee arthritis symptom relief effect was evaluated every 4 weeks.

Assessment was conducted by K-Western Ontario and McMaster Universities (WOMAC), which assesses visual analogue scale (VAS) for pain of pain and joint function, and joint pain with arthritis. Osteoarthritis index was used. VAS is an index of knee pain, showing a 10-cm visual horizontal line from 0 to 10 points, indicating pain between the painless state (0 point) and the most severe pain (10 points).

The K-WOMAC was measured only for pain and was measured at a maximum of 20 points.

The results of the 0th and 12th weeks of the VAS and K-WOMAC pain index summation indices and the significance analysis results are shown in Table 1 below.

Evaluation variable Experimental group VAS

0 Week Mean (SD) 4.0 (2.0)
12 weeks Mean (SD) 2.5 (1.5) p-value 0.0003 K-WOMAC pain

0 Week Mean (SD) 10.5 (4.1)
12 weeks Mean (SD) 8.4 (2.9) p-value 0.0021

As a result of the experiment, it was confirmed that the VAS and K-WOMAC pain items were lowered at 12 weeks compared to the control (0 weeks), as shown in Table 1 above.

[Preparation Example 1: Preparation of food composition for symptom of knee arthritis and pain relief]

In this Example, the preparation of a knee joint symptom and a pain relieving food composition containing the cetylated fatty acid prepared in Example 1 were prepared.

(1) health drinks manufacturing

0.0001% by weight of honey, 0.0002% by weight of chitosanic acid amide, 0.0004% by weight of nicotinic acid amide, 0.0001% by weight of sodium riboflavin hydrochloride, 0.0001% by weight of pyridoxine hydrochloride, 0.001% by weight of inositol, 0.002% by weight of orthoacetic acid, And 89.7362% by weight of water were blended to prepare a health drink by a conventional method.

(2) health supplement manufacturing

0.05% of L-methionine, 0.7% of L-methionine, 0.7% of L-lactose, 22.2% of lactose, 1.85% of corn starch, And 10% by weight of cetylated fatty acid were mixed to prepare a refillable health supplement food by a conventional method.

Claims (6)

  1. 0.0001% by weight of honey, 0.0002% by weight of chitosanic acid amide, 0.0004% by weight of nicotinic acid amide, 0.0001% by weight of sodium riboflavin hydrochloride, 0.0001% by weight of pyridoxine hydrochloride, 0.001% by weight of inositol, 0.002% by weight of orthoacetic acid, Water and 89.7362% by weight of water.
  2. A starch hydrolyzate, a starch hydrolyzate, a starch hydrolyzate, a starch hydrolyzate, a starch hydrolyzate, a starch hydrolyzate, a starch hydrolyzate, a starch hydrolyzate, And 10% by weight of cetylated fatty acids.
  3. delete
  4. delete
  5. delete
  6. delete
KR1020140052533A 2014-04-30 2014-04-30 Food composition with cetylated fatty for alleviaton of symptoms and pains KR101514011B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020140052533A KR101514011B1 (en) 2014-04-30 2014-04-30 Food composition with cetylated fatty for alleviaton of symptoms and pains

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140052533A KR101514011B1 (en) 2014-04-30 2014-04-30 Food composition with cetylated fatty for alleviaton of symptoms and pains

Publications (1)

Publication Number Publication Date
KR101514011B1 true KR101514011B1 (en) 2015-04-21

Family

ID=53053765

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020140052533A KR101514011B1 (en) 2014-04-30 2014-04-30 Food composition with cetylated fatty for alleviaton of symptoms and pains

Country Status (1)

Country Link
KR (1) KR101514011B1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569676A (en) * 1995-05-24 1996-10-29 Diehl; Harry W. Method for the treatment of osteoarthritis
US8258184B1 (en) * 2002-03-21 2012-09-04 Botanoceuticals, Inc. Use of vegetable butter-based cetyl myristoleate for treating osteoarthritis and other musculoskeletal disease conditions and injuries
EP2379175B1 (en) * 2009-01-12 2013-07-17 Council of Scientific & Industrial Research A process for preparation of hexadecyl cis-9-tetradecenoate and hexadecyl cis-10-tetradecenoate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569676A (en) * 1995-05-24 1996-10-29 Diehl; Harry W. Method for the treatment of osteoarthritis
US8258184B1 (en) * 2002-03-21 2012-09-04 Botanoceuticals, Inc. Use of vegetable butter-based cetyl myristoleate for treating osteoarthritis and other musculoskeletal disease conditions and injuries
EP2379175B1 (en) * 2009-01-12 2013-07-17 Council of Scientific & Industrial Research A process for preparation of hexadecyl cis-9-tetradecenoate and hexadecyl cis-10-tetradecenoate

Similar Documents

Publication Publication Date Title
CN1282419C (en) Oil composition
CA1334004C (en) Essential fatty acid compositions
JP2699083B2 (en) Lithium salt-containing pharmaceutical composition
US9220290B2 (en) Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
EP1711173A2 (en) Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
HU229230B1 (en) Herpes simplex virus, and other pharmaceutical compositions for the treatment of infections caused by diseases
KR20040019011A (en) Zinc containing compositions for anti-viral use
CN1438884A (en) Therapeutic combinations of fatty acids
EA004312B1 (en) Use of EPA and / or DHA fatty acids and / or their ethyl esters for the manufacture of a medicament for reducing mortality of patients with myocardial infarction
WO2009091538A3 (en) Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia
HU0401343A2 (en) Coenzyme Q-containing compositions and their use and eicosapentaenoic acid (EPA)
JP2002179586A (en) Lipase inhibitor
Senapati et al. Evening primrose oil is effective in atopic dermatitis: a randomized placebo-controlled trial
CA2124605C (en) Prevention and improvement of medical symptoms caused by leucotriene b4
JP4847756B2 (en) Human β-defensin secretion promoter
JP4243353B2 (en) Zinc salts of conjugated linoleic acids for use in the treatment of skin diseases
DE69633818T2 (en) of a disease means to use for prevention or treatment of abnormalities of the cartilage tissue caused by
CN106902104A (en) Method for treating neurotrauma
US20130065867A1 (en) Compositions and methods for using same for treating posterior blepharitis
JPWO2003074043A1 (en) Body temperature raising agents
JPWO2005074960A1 (en) Functional drinks and compositions
CN101765427A (en) Improving memory in subjects with mini-mental state examination of 24-26
CN1168104A (en) Remedy for dermatitis
US9000039B2 (en) Sn-1(3) monoacylglycerides and lipid absorption
CN101199462B (en) Scouring bath product suited for skin trait of infant 7 to 12 months old and process for preparing same

Legal Events

Date Code Title Description
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20180416

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20190415

Year of fee payment: 5